Share on StockTwits

Ophthotech Corp (NASDAQ:OPHT) CEO David R. Guyer sold 15,034 shares of the stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $41.08, for a total transaction of $617,596.72. The sale was disclosed in a filing with the SEC, which is available at this link.

Ophthotech Corp (NASDAQ:OPHT) traded down 0.26% on Thursday, hitting $40.925. 55,108 shares of the company’s stock traded hands. Ophthotech Corp has a 1-year low of $22.61 and a 1-year high of $47.99. The stock has a 50-day moving average of $40.72 and a 200-day moving average of $35.06. The company’s market cap is $1.364 billion.

Ophthotech Corp (NASDAQ:OPHT) last released its earnings data on Tuesday, May 13th. The company reported ($0.64) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.67) by $0.03. Analysts expect that Ophthotech Corp will post $-2.11 EPS for the current fiscal year.

OPHT has been the subject of a number of recent research reports. Analysts at Morgan Stanley raised their price target on shares of Ophthotech Corp from $79.00 to $99.00 in a research note on Tuesday, May 20th. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Ophthotech Corp from $40.00 to $51.00 in a research note on Tuesday, May 20th. They now have an “overweight” rating on the stock. Finally, analysts at Stifel Nicolaus raised their price target on shares of Ophthotech Corp from $55.00 to $58.00 in a research note on Tuesday, May 20th. They now have a “buy” rating on the stock.

Ophthotech Corporation is a biopharmaceutical company specializing in the development of therapeutics to treat diseases of the eye.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.